Citations (94)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Chiara Gasteiger, Alfons A. den Broeder, Sarah Stewart, Norina Gasteiger, Urte Scholz, Nicola Dalbeth & Keith J. Petrie. (2023) The mode of delivery and content of communication strategies used in mandatory and non-mandatory biosimilar transitions: a systematic review with meta-analysis. Health Psychology Review 17:1, pages 148-168.
Read now
Read now
Palak V. Patel, Caitlin G. Purvis, Ramiz N. Hamid & Steven R. Feldman. (2022) Non-medical switching in dermatology: cost-conscious policy or an affront to patient safety?. Journal of Dermatological Treatment 33:6, pages 2707-2710.
Read now
Read now
Carla Felice, Daniela Pugliese & Alessandro Armuzzi. (2019) The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases. Expert Opinion on Biological Therapy 19:10, pages 967-969.
Read now
Read now
Akram Hernández-Vásquez, Christoper A. Alarcon-Ruiz, Guido Bendezu-Quispe, Daniel Comandé & Diego Rosselli. (2018) A bibliometric analysis of the global research on biosimilars. Journal of Pharmaceutical Policy and Practice 11:1.
Read now
Read now
Lieven Pouillon, Marie Socha, Beatrice Demore, Nathalie Thilly, Vered Abitbol, Silvio Danese & Laurent Peyrin-Biroulet. (2018) The nocebo effect: a clinical challenge in the era of biosimilars. Expert Review of Clinical Immunology 14:9, pages 739-749.
Read now
Read now
Neh Nupur, Nidhi Chhabra, Rozaleen Dash & Anurag S. Rathore. (2018) Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study. mAbs 10:1, pages 143-158.
Read now
Read now
John Waller, Emma Sullivan, James Piercy, Christopher M Black & Sumesh Kachroo. (2017) Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany. Patient Preference and Adherence 11, pages 519-530.
Read now
Read now
Dae Hyun Yoo. (2017) CT-P13 in the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology 13:7, pages 653-666.
Read now
Read now
Articles from other publishers (86)
Gladys Rodriguez, Joan Mancuso, Gary H. Lyman, Fatima Cardoso, Zeina Nahleh, Julie M. Vose, Julie R. Gralow, Michael Francisco & Shimere Sherwood. (2023) ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology. JCO Oncology Practice 19:7, pages 411-419.
Crossref
Crossref
Allan GibofskyGary JacobsonArchie FranklinShannan O’Hara-LeviLaurent Peyrin-BirouletMelissa McGrathDorothy McCabe. (2023) An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars. Journal of Managed Care & Specialty Pharmacy 29:4, pages 343-349.
Crossref
Crossref
Austin Kulasekararaj, Robert Brodsky, Alexander Kulagin & Jun Ho Jang. (2022) Biosimilars in rare diseases: a focus on paroxysmal nocturnal hemoglobinuria. Haematologica 108:5, pages 1232-1243.
Crossref
Crossref
Wallace J Brownlee, Christian Wolf, Hans-Peter Hartung, Theo Dingermann, Nadia Anshasi, Richard AC Clark, Maria Trojano, Krzysztof Selmaj, Bernard MJ Uitdehaag, Carmen Tur, Jens Wuerfel, Gabriele Dallmann, Julian Witte, Martina Sintzel, Olga Bobrovnikova & Jeffrey A Cohen. (2022) Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations. Multiple Sclerosis Journal 28:14, pages 2177-2189.
Crossref
Crossref
Chiara Gasteiger, Norina Gasteiger & Keith J. Petrie. (2022) Pharmacists' confidence in explaining biosimilars to patients before a nationwide medicine change: A cross-sectional study. Exploratory Research in Clinical and Social Pharmacy 8, pages 100199.
Crossref
Crossref
Chiara Gasteiger & Keith J. Petrie. (2022) Moving forward: Implementing health psychology research to improve patient acceptance of biosimilars. Research in Social and Administrative Pharmacy 18:10, pages 3860-3863.
Crossref
Crossref
Matthew L. Hrin, Jeremy K. Bray & Steven R. Feldman. (2022) Reassurance Techniques Do Not Significantly Impact Confidence in Biosimilars for Psoriasis: A Survey of a Convenience Sample of Individuals with Self-Identified Psoriasis. Dermatology and Therapy 12:9, pages 2173-2180.
Crossref
Crossref
Stefan Schreiber, Luis Puig, João Gonçalves, Philip J. Mease, Remo Panaccione & Paul Emery. (2022) Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases. Seminars in Arthritis and Rheumatism 55, pages 152023.
Crossref
Crossref
David Young, Fraser Cummings & Susan Latter. (2022) Patient perspectives of successful adalimumab biosimilar transitioning in Crohn’s disease: an interview study. European Journal of Hospital Pharmacy, pages ejhpharm-2022-003371.
Crossref
Crossref
Lina Yossef, Molly Wright, Jason Benedict, Grant A. Morris, Megan McNicol, Brendan Boyle, Jennifer L. Dotson, Hilary K. Michel & Ross M. Maltz. (2022) Patient and Caregivers’ Perspectives on Biosimilar Use in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 75:1, pages 59-63.
Crossref
Crossref
Meera Varma, Anna Birna Almarsdóttir & Louise C. Druedahl. (2022) “Biosimilar, so it looks alike, but what does it mean?” A qualitative study of Danish patients' perceptions of biosimilars. Basic & Clinical Pharmacology & Toxicology 130:5, pages 581-591.
Crossref
Crossref
Nicoletta Luciano, Enrico Fusaro, Maria Chiara Ditto, Aurora Ianniello, Emanuela Bellis, Cosimo Bruni, Ombretta Viapiana, Elisa Gremese, Alberto Migliore, Ester Romoli, Ludovica Conforti, Marcello Govoni, Marco Matucci-Cerinic & Carlo Selmi. (2022) Effectiveness of SB4 transition from originator etanercept in rheumatoid arthritis and axial spondyloarthritis: A subgroup analysis from the BENEFIT study. Rheumatology and Immunology Research 3:1, pages 31-37.
Crossref
Crossref
Zeina Nahleh, Gary H. Lyman, Richard L. Schilsky, Douglas E. Peterson, Scott T. Tagawa, Mariana Chavez-MacGregor, R. Bryan Rumble & Shilpi Gupta. (2022) Use of Biosimilar Medications in Oncology. JCO Oncology Practice 18:3, pages 177-186.
Crossref
Crossref
Gina Wong, Katie Wang, Mark Pasetka, Liying Zhang, Julia Lou, Habeeb Majeed, Jerome Flores, Emily Lam & Carlo DeAngelis. (2022) The Real-World Experience of the Biosimilar (Grastofil®) to the Reference Biologic (Neupogen®) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study. Current Oncology 29:3, pages 1349-1369.
Crossref
Crossref
Tore K. Kvien, Kashyap Patel & Vibeke Strand. (2022) The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Seminars in Arthritis and Rheumatism 52, pages 151939.
Crossref
Crossref
Yannick Vandenplas, Liese Barbier, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto & Isabelle Huys. (2022) Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care. Frontiers in Pharmacology 12.
Crossref
Crossref
Gina Wong, Liying Zhang, Habeeb Majeed, Yasmeen Razvi, Carlo DeAngelis, Emily Lam, Erin McKenzie, Katie Wang & Mark Pasetka. (2020) A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga®) to the reference biologic (Neulasta®). Journal of Oncology Pharmacy Practice 28:1, pages 5-16.
Crossref
Crossref
Bharati Bhardwaja, Shilpa Klocke, Ekim Ekinci, Adam Jackson, Scott Kono & Kari L. Olson. (2021) Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System. BioDrugs 36:1, pages 1-11.
Crossref
Crossref
Johanna Mielke & Byron Jones. 2022. Principles and Practice of Clinical Trials. Principles and Practice of Clinical Trials
1237
1260
.
Chiara Gasteiger, Urte Scholz, Keith J. Petrie & Nicola Dalbeth. (2021) A bio-what? Medical companions’ perceptions towards biosimilars and information needs in rheumatology. Rheumatology International 42:11, pages 1993-2002.
Crossref
Crossref
Ross M Maltz, Megan McNicol, Laura Wingate, Sarah Buchanan, Angela Sandell, Sandra C Kim & David T Rubin. (2021) There Is No Substitute for Effective Education About Biosimilars. Crohn's & Colitis 360 3:4.
Crossref
Crossref
Suz Jack Chan, Hui Yee Yeo, Lisa K. Stamp, Gareth J. Treharne & Carlo A. Marra. (2020) What Are the Preferences of Patients With Rheumatoid Arthritis for Treatment Modification? A Scoping Review. The Patient - Patient-Centered Outcomes Research 14:5, pages 505-532.
Crossref
Crossref
Jimmy K Limdi & Francis A Farraye. (2021) The Great Debate With IBD Biosimilars. Crohn's & Colitis 360 3:3.
Crossref
Crossref
Jingyan Yang, Rongzhe Liu, Varun Ektare, Jennifer Stephens & Ahmed Shelbaya. (2021) Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives. Applied Health Economics and Health Policy 19:4, pages 605-618.
Crossref
Crossref
Félix Lobo & Isabel Río-Álvarez. (2021) Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain. Pharmaceuticals 14:3, pages 283.
Crossref
Crossref
Miguel Ángel Abad Hernández, José Luis Andreu, Alejandro Balsa Criado, Federico Díaz-González, José Vicente Moreno Muelas, Rubén Queiro Silva & Juan J. Gómez-Reino. (2021) Update of the position paper of the Spanish Society of Rheumatology on biosimilar drugs. Reumatología Clínica (English Edition) 17:3, pages 160-169.
Crossref
Crossref
Miguel Ángel Abad Hernández, José Luis Andreu, Alejandro Balsa Criado, Federico Díaz-González, José Vicente Moreno Muelas, Rubén Queiro Silva & Juan J. Gómez-Reino. (2021) Actualización del Documento de posicionamiento de la Sociedad Española de Reumatología sobre fármacos biosimilares. Reumatología Clínica 17:3, pages 160-169.
Crossref
Crossref
Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto & Isabelle Huys. (2021) Informing Patients about Biosimilar Medicines: The Role of European Patient Associations. Pharmaceuticals 14:2, pages 117.
Crossref
Crossref
Davide Mazzoni, Claudia Vener, Ketti Mazzocco, Dario Monzani & Gabriella Pravettoni. (2021) The Psychological Risks Associated With the Non-medical Switch From Biologics to Biosimilars. Frontiers in Psychology 12.
Crossref
Crossref
Chiara Gasteiger, Maria Lobo, Nicola Dalbeth & Keith J. Petrie. (2020) Patients’ beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch. Rheumatology International 41:1, pages 163-171.
Crossref
Crossref
Lynn Weekes. 2020. Biologics, Biosimilars, and Biobetters. Biologics, Biosimilars, and Biobetters
237
251
.
Rovshan Ismailov, Steven Simoens & Zaytuna Khasanova. (2020) Greater awareness of biosimilars and shared decision-making among patients attending rheumatology practices in Colorado, United States: Real-world data. World Journal of Rheumatology 10:1, pages 1-10.
Crossref
Crossref
Charles L Bennett, Martin W Schoen, Shamia Hoque, Bartlett J Witherspoon, David M Aboulafia, Catherine S Hwang, Paul Ray, Paul R Yarnold, Brian K Chen, Benjamin Schooley, Matthew A Taylor, Michael D Wyatt, William J Hrushesky & Y Tony Yang. (2020) Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. The Lancet Oncology 21:12, pages e575-e588.
Crossref
Crossref
Anna Hester, Paul Gaß, Peter A. Fasching, Anne Katrin Krämer, Johannes Ettl, Joachim Diessner, Achim Wöckel, Tobias Egger, Katja Stock, Jutta Redlin, Monika Andraschko, Nadia Harbeck & Rachel Würstlein. (2020) Trastuzumab Biosimilars in the Therapy of Breast Cancer – “Real World” Experiences from four Bavarian University Breast Centres. Geburtshilfe und Frauenheilkunde 80:09, pages 924-931.
Crossref
Crossref
Chiara Gasteiger, Annie S. K. Jones, Maria Kleinstäuber, Maria Lobo, Rob Horne, Nicola Dalbeth & Keith J. Petrie. (2020) Effects of Message Framing on Patients’ Perceptions and Willingness to Change to a Biosimilar in a Hypothetical Drug Switch. Arthritis Care & Research 72:9, pages 1323-1330.
Crossref
Crossref
Catherine M. Lockhart, Cara L. McDermott, Thomas Felix, Nancy D. Lin, Mark J. Cziraky, Aaron B. Mendelsohn & Jeffrey S. Brown. (2019) Barriers and facilitators to conduct high‐quality, large‐scale safety and comparative effectiveness research: The Biologics and Biosimilars Collective Intelligence Consortium experience. Pharmacoepidemiology and Drug Safety 29:7, pages 811-813.
Crossref
Crossref
Shubha BhatSarah AltajarDivya ShankarToni ZahorianRegine RobertTaha QaziBhavesh ShahFrancis A. Farraye. (2020) Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb. Journal of Managed Care & Specialty Pharmacy 26:4, pages 410-416.
Crossref
Crossref
Emma Foreman, Himanshu Patel, Jim Siderov, Jatinder Harchowal, Joseph Bubalo & Alexandre Chan. (2020) A survey of global biosimilar implementation practice conducted by the International Society of Oncology Pharmacy Practitioners. Journal of Oncology Pharmacy Practice 26:3_suppl, pages 22-32.
Crossref
Crossref
Ibrahim N. Muhsen, Shahrukh K. Hashmi, Dietger Niederwieser, Nicolaus Kroeger, Samir Agrawal, Marcelo C. Pasquini, Yoshiko Atsuta, Karen K. Ballen, Adriana Seber, Wael Saber, Mohamed A. Kharfan-Dabaja, Walid Rasheed, Shinichiro Okamoto, Nandita Khera, William A. Wood, Mickey B. C. Koh, Hildegard Greinix, Yoshihisa Kodera, Jeff Szer, Mary M. Horowitz, Daniel Weisdorf & Mahmoud Aljurf. (2019) Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. Bone Marrow Transplantation 55:4, pages 698-707.
Crossref
Crossref
Tom Kovitwanichkanont, Sudha Raghunath, Dorothy Wang, Leo Kyi, Silvana Pignataro, Susan Morton, Eric Morand & Michelle Leech. (2020) Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis. Internal Medicine Journal 50:3, pages 374-377.
Crossref
Crossref
Vincent Haghnejad, Catherine Le Berre, Yoann Dominique, Camille Zallot, Francis Guillemin & Laurent Peyrin-Biroulet. (2020) Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease. Digestive and Liver Disease 52:3, pages 281-288.
Crossref
Crossref
HoUng Kim, Rieke Alten, Luisa Avedano, Axel Dignass, Fernando Gomollón, Kay Greveson, Jonas Halfvarson, Peter M. Irving, Jørgen Jahnsen, Péter L. Lakatos, JongHyuk Lee, Souzi Makri, Ben Parker, Laurent Peyrin-Biroulet, Stefan Schreiber, Steven Simoens, Rene Westhovens, Silvio Danese & Ji Hoon Jeong. (2020) The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 80:2, pages 99-113.
Crossref
Crossref
Johanna Mielke & Byron Jones. 2020. Principles and Practice of Clinical Trials. Principles and Practice of Clinical Trials
1
24
.
Nicolas Petitdidier, Jenny Tannoury, Nicola de’Angelis, Charlotte Gagniere, Anne Hulin, Hugo Rotkopf, Farida Mesli, Francesco Brunetti, Iradj Sobhani & Aurelien Amiot. (2019) Patients’ perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. Digestive and Liver Disease 51:12, pages 1652-1660.
Crossref
Crossref
Luana Colloca, Remo Panaccione & T. Kevin Murphy. (2019) The Clinical Implications of Nocebo Effects for Biosimilar Therapy. Frontiers in Pharmacology 10.
Crossref
Crossref
Daniel J. Kent, Cheryl N. McMahill-Walraven, Catherine A. Panozzo, Pamala A. Pawloski, Kevin Haynes, James Marshall, Jeffrey Brown, Bernadette EichelbergerCatherine M. Lockhart. (2019) Descriptive Analysis of Long- and Intermediate-Acting Insulin and Key Safety Outcomes in Adults with Type 2 Diabetes Mellitus. Journal of Managed Care & Specialty Pharmacy 25:11, pages 1162-1171.
Crossref
Crossref
Cheryl N. McMahill-WalravenDaniel J. KentCatherine A. PanozzoPamala A. PawloskiKevin HaynesJames MarshallJeffrey BrownBernadette EichelbergerCatherine M. Lockhart. (2019) Harnessing the Biologics and Biosimilars Collective Intelligence Consortium to Evaluate Patterns of Care. Journal of Managed Care & Specialty Pharmacy 25:11, pages 1156-1161.
Crossref
Crossref
Léa Frantzen, Jean-David Cohen, Sonia Tropé, Morgane Beck, Audrey Munos, Mariannick Sittler, Rita Diebolt, Isabelle Metzler, Laurent Arnaud, Jacques-Éric Gottenberg & Christelle Sordet. (2019) Information et perception des patients au sujet des biosimilaires en rhumatologie. Revue du Rhumatisme 86:6, pages 591-596.
Crossref
Crossref
Filipe César Araújo, João Gonçalves & João Eurico Fonseca. (2019) Biosimilars in rheumatology. Pharmacological Research 149, pages 104467.
Crossref
Crossref
Rovshan M Ismailov, Zaytuna D Khasanova & Pere Gascon. (2019) Knowledge and awareness of biosimilars among oncology patients in Colorado, USA. Future Oncology 15:22, pages 2577-2584.
Crossref
Crossref
Laurence GreeneRubina M. SinghMary Jo CardenCaroline O. PardoGary R. Lichtenstein. (2019) Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals. Journal of Managed Care & Specialty Pharmacy 25:8, pages 904-912.
Crossref
Crossref
Ioanna Spanou, Theodoros Mavridis & Dimos D. Mitsikostas. (2019) Nocebo in Biosimilars and Generics in Neurology: A Systematic Review. Frontiers in Pharmacology 10.
Crossref
Crossref
Léa Frantzen, Jean-David Cohen, Sonia Tropé, Morgane Beck, Audrey Munos, Marie-Annick Sittler, Rita Diebolt, Isabelle Metzler & Christelle Sordet. (2019) Patients’ information and perspectives on biosimilars in rheumatology: A French nation-wide survey. Joint Bone Spine 86:4, pages 491-496.
Crossref
Crossref
Lieven Pouillon, Silvio Danese, Ailsa Hart, Gionata Fiorino, Marjorie Argollo, Carlo Selmi, Carmelo Carlo-Stella, Damien Loeuille, Antonio Costanzo, Anthony Lopez, Elena Vegni, Simona Radice, Daniela Gilardi, Marie Socha, Maria Fazio, Marien González-Lorenzo, Stefanos Bonovas, Fernando Magro & Laurent Peyrin-Biroulet. (2019) Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. Alimentary Pharmacology & Therapeutics 49:9, pages 1181-1187.
Crossref
Crossref
Gionata Fiorino, Flavio Caprioli, Marco Daperno, Filippo Mocciaro, Mariabeatrice Principi, Angelo Viscido, Massimo Claudio Fantini, Ambrogio Orlando, Claudio Papi, Vito Annese, Silvio Danese, Maurizio Vecchi, Fernando Rizzello, Alessandro Armuzzi, Salvatore Leone, Enrica Previtali, Marina Aloi, Patrizia Alvisi, Elisabetta Antonelli, Sandro Ardizzone, Marco Astegiano, Monia Baldoni, Marina Beltrami, Livia Biancone, Giorgia Bodini, Andrea Buda, Fabrizio Bossa, Fiammetta Bracci, Emma Calabrese, Maria Cappello, Fabiana Castiglione, Carolina Ciacci, Michele Cicala, Rachele Ciccocioppo, Michele Comberlato, Claudio Camillo Cortelezzi, Rocco Cosintino, Francesco Costa, Giuseppe Costantino, Salvatore Cucchiara, Antonio Cuomo, Renata D’Incà, Maria Carla Di Paolo, Antonio Di Sabatino, Antonio Di Sario, Giuseppe Frieri, Walter Fries, Antonio Gasbarrini, Andrea Geccherle, Paolo Gionchetti, Maria Giovanna Graziani, Laurino Grossi, Luisa Guidi, Gianni Imperiali, Giovanni Latella, Paolo Lionetti, Gaetano Inserra, Giovanni Maconi, Francesco Manguso, Marco Marino, Mauro Mastronardi, Silvia Mazzuoli, Gianmichele Meucci, Marco Mendolaro, Monica Milla, Giammarco Mocci, Giovanni Monteleone, Francesco Neri Bortoluzzi, Cristiano Pagnini, Luca Pastorelli, Roberta Pica, Simona Piergallini, Antonello Privitera, Sara Renna, Davide Giuseppe Ribaldone, Chiara Ricci, Antonio Rispo, Rodolfo Rocca, Claudio Romano, Marco Romano, Giovanni Russo, Renato Sablich, Simone Saibeni, Edoardo Savarino, Maria Lia Scribano, Rocco Spagnuolo, Elisa Stasi, Maria Maddalena Terpin, Anna Testa, Daniela Valpiani, Angela Variola, Piero Vernia, Giovanna Vitale & Giorgio Zoli. (2019) Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 51:5, pages 632-639.
Crossref
Crossref
Fumikata Hara, Kentaro Tajima & Kosuke Tanabe. (2019) Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer. Future Oncology 15:12, pages 1353-1361.
Crossref
Crossref
Guro L. Goll, Espen A. Haavardsholm & Tore K. Kvien. (2019) Confiance des rhumatologues quant au passage à un biosimilaire. Revue du Rhumatisme 86:2, pages 115-118.
Crossref
Crossref
Bente Glintborg, Anne Gitte Loft, Emina Omerovic, Oliver Hendricks, Asta Linauskas, Jakob Espesen, Kamilla Danebod, Dorte Vendelbo Jensen, Henrik Nordin, Emil Barner Dalgaard, Stavros Chrysidis, Salome Kristensen, Johnny Lillelund Raun, Hanne Lindegaard, Natalia Manilo, Susanne Højmark Jakobsen, Inger Marie Jensen Hansen, Dorte Dalsgaard Pedersen, Inge Juul Sørensen, Lis Smedegaard Andersen, Jolanta Grydehøj, Frank Mehnert, Niels Steen Krogh & Merete Lund Hetland. (2019) To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Annals of the Rheumatic Diseases 78:2, pages 192-200.
Crossref
Crossref
Alessandro Armuzzi, Luisa Avedano, Kay Greveson & Taegyun Kang. (2019) Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies. Journal of Crohn's and Colitis 13:2, pages 259-266.
Crossref
Crossref
John W. Cook, Megan K. McGrath, Margie D. Dixon, Jeffrey M. Switchenko, R. Donald Harvey & Rebecca D. Pentz. (2019) Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing. Therapeutic Advances in Medical Oncology 11, pages 175883591881833.
Crossref
Crossref
Johanna Sigaux, Luca Semerano & Marie-Christophe Boissier. (2019) Faut-il substituer un traitement en cours par un biosimilaire coûte que coûte ?. Revue du Rhumatisme 86:1, pages 1-4.
Crossref
Crossref
Lisa Gervais, Luke L. McLean, Michelle L. Wilson, Carol Cameron, Lee Curtis, Vikki Garrick, Kat Armstrong, Rachel Tayler, Paul Henderson, Richard Hansen, Iain Chalmers, David C. Wilson & Richard K. Russell. (2018) Switching From Originator to Biosimilar Infliximab in Paediatric Inflammatory Bowel Disease Is Feasible and Uneventful. Journal of Pediatric Gastroenterology & Nutrition 67:6, pages 745-748.
Crossref
Crossref
Johanna Sigaux, Luca Semerano & Marie-Christophe Boissier. (2018) Switch to a biosimilar: Whatever the cost?. Joint Bone Spine 85:6, pages 651-654.
Crossref
Crossref
Chadi Nabhan, Amy Valley & Bruce A. Feinberg. (2018) Barriers to Oncology Biosimilars Uptake in the United States. The Oncologist 23:11, pages 1261-1265.
Crossref
Crossref
Yelena Y Janjigian, Marco Bissig, Giuseppe Curigliano, Jennifer Coppola & Mark Latymer. (2018) Talking to patients about biosimilars. Future Oncology 14:23, pages 2403-2414.
Crossref
Crossref
Eduardo Cazap, Ira Jacobs, Ali McBride, Robert Popovian & Karol Sikora. (2018) Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust. The Oncologist 23:10, pages 1188-1198.
Crossref
Crossref
Joseph Tariman. (2018) Biosimilars: Exploring the History, Science, and Progress. Clinical Journal of Oncology Nursing 22:5, pages 5-12.
Crossref
Crossref
Guro L. Goll, Espen A. Haavardsholm & Tore K. Kvien. (2018) The confidence of rheumatologists about switching to biosimilars for their patients. Joint Bone Spine 85:5, pages 507-509.
Crossref
Crossref
Lars Erik Kristensen, Rieke Alten, Luis Puig, Sandra Philipp, Tore K. Kvien, Maria Antonia Mangues, Frank van den Hoogen, Karel Pavelka & Arnold G. Vulto. (2018) Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. BioDrugs 32:5, pages 397-404.
Crossref
Crossref
David Pineles, Lisa Malter, Peter S. Liang, Amy Arsuaga, Brian Bosworth, David P. Hudesman & Shannon Chang. (2018) The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease. European Journal of Clinical Pharmacology 74:10, pages 1361-1362.
Crossref
Crossref
Francisco J Esteva, Toshiaki Saeki, HoUng Kim & Justin Stebbing. (2018) Efficacy and safety of the trastuzumab biosimilar candidate CT-P6. Future Oncology 14:19, pages 1909-1919.
Crossref
Crossref
Filipe C. Araújo, Joao Eurico Eurico Fonseca & Joao Goncalves. (2018) Switching to Biosimilars in Inflammatory Rheumatic Conditions: Current Knowledge. EMJ Rheumatology, pages 66-74.
Crossref
Crossref
P. Yamauchi, J. Crowley, P. Kaur, L. Spelman & R. Warren. (2018) Biosimilars: what the dermatologist should know. Journal of the European Academy of Dermatology and Venereology 32:7, pages 1066-1074.
Crossref
Crossref
Michael Epstein. (2018) Food and Drug Administration guidances on biosimilars: an update for the gastroenterologist. Therapeutic Advances in Gastroenterology 11, pages 175628481879960.
Crossref
Crossref
Evelien Moorkens, Arnold G. Vulto, Isabelle Huys, Pieter Dylst, Brian Godman, Simon Keuerleber, Barbara Claus, Maria Dimitrova, Guenka Petrova, Ljiljana Sović-Brkičić, Juraj Slabý, Robin Šebesta, Ott Laius, Allan Karr, Morgane Beck, Jaana E. Martikainen, Gisbert W. Selke, Susan Spillane, Laura McCullagh, Gianluca Trifirò, Patricia Vella Bonanno, Asbjørn Mack, Antra Fogele, Anita Viksna, Magdalena Władysiuk, Helder Mota-Filipe, Dmitry Meshkov, Marija Kalaba, Simona Mencej Bedrač, Jurij Fürst, Corrine Zara, Peter Skiöld, Einar Magnússon & Steven Simoens. (2017) Policies for biosimilar uptake in Europe: An overview. PLOS ONE 12:12, pages e0190147.
Crossref
Crossref
Mourad F. Rezk & Burkhard Pieper. (2017) Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect. Rheumatology and Therapy 4:2, pages 209-218.
Crossref
Crossref
Rakesh ChopraGilberto Lopes. (2017) Improving Access to Cancer Treatments: The Role of Biosimilars. Journal of Global Oncology 3:5, pages 596-610.
Crossref
Crossref
Eline van Overbeeke, Birgit De Beleyr, Jan de Hoon, Rene Westhovens & Isabelle Huys. (2017) Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists. BioDrugs 31:5, pages 447-459.
Crossref
Crossref
Mohammed I. Aladul, Raymond W. Fitzpatrick & Stephen R. Chapman. (2017) Patients’ Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey. BioDrugs 31:5, pages 439-446.
Crossref
Crossref
Robert M. Rifkin & Susan R. Peck. (2017) Biosimilars: Implications for Clinical Practice. Journal of Oncology Practice 13:9_suppl, pages 24s-31s.
Crossref
Crossref
Till Uhlig & Guro L. Goll. (2017) Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Rheumatology 56:suppl_4, pages iv49-iv62.
Crossref
Crossref
Won Seog Kim, Michinori Ogura, Hyuk-Chan Kwon & Dasom Choi. (2017) Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer. Future Oncology 13:15s, pages 17-29.
Crossref
Crossref
Cristina Scavone, Liberata Sportiello, Liberato Berrino, Francesco Rossi & Annalisa Capuano. (2017) Biosimilars in the European Union from comparability exercise to real world experience: What we achieved and what we still need to achieve. Pharmacological Research 119, pages 265-271.
Crossref
Crossref
Amy Hemmington, Nicola Dalbeth, Paul Jarrett, Alan G. Fraser, Reuben Broom, Peter Browett & Keith J. Petrie. (2017) Medical specialists' attitudes to prescribing biosimilars. Pharmacoepidemiology and Drug Safety 26:5, pages 570-577.
Crossref
Crossref
Emma Sullivan, James Piercy, John Waller, Christopher M. Black & Sumesh Kachroo. (2017) Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany. PLOS ONE 12:4, pages e0175826.
Crossref
Crossref
Kuan Peng, Joseph Blais, Nicole Pratt, Jeff Jianfei Guo, Jodie B. Hillen, Tyman Stanford, Michael Ward, Edward Chia-Cheng Lai, Ju-Young Shin, Xinning Tong, Min Fan, Franco W.T. Cheng, Jing Wu, Winnie Wan Yin Yeung, Chak-Sing LAU, Wai Keung Leung, Ian Chi Kei Wong & Xue Li. (2022) Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis. SSRN Electronic Journal.
Crossref
Crossref